Phase II Study in Patients With Operable Breast Cancer
Status:
Unknown status
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and
trastuzumab in patients with operable breast cancer. Patients will be treated with the
combination for 18 weeks, followed by surgery.